Skip to content

IMRN

Immuron Ltd.

NASDAQ · Healthcare · Biotechnology · AU

$0.96
−2.62%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+23.1%
EBITDA
+99.4%
EPS
+96.9%

Three-year CAGR

Revenue
+61.1%
EBITDA
+12.7%
EBIT
+13.3%
Net income
+28.0%
EPS
+44.4%
Free cash flow
+51.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026